DEF: SI-BONE Reports Strong 2024 Revenue Growth and Improved Profitability, Announces Annual Meeting

SI-BONE's 2024 saw a 20% revenue increase, significant physician adoption of iFuse procedures, and substantial improvements in net loss and adjusted EBITDA.

Summary

• SI-BONE, Inc. invites stockholders to its virtual Annual Meeting on June 5, 2025.
• The company achieved worldwide revenue of $167.2 million in 2024, a 20% increase over 2023.
• Over 2,000 physicians performed an iFuse procedure in 2024, representing a 25% increase year-over-year.
• The company surpassed 115,000 procedures performed by over 4,300 physicians worldwide since its inception.
• SI-BONE improved its net loss by approximately 29% and adjusted EBITDA by approximately 71% year-over-year.
• The company achieved positive adjusted EBITDA in the fourth quarter of 2024.
• SI-BONE exited 2024 with a strong balance sheet, holding approximately $150 million in cash and equivalents.
• The company launched iFuse INTRA, iFuse Bedrock Granite 9.5, and iFuse TORQ TNT in 2024.
• Transitional Pass-Through payment status was granted effective January 1, 2025, for Granite outpatient procedures.
• SI-BONE received its third Breakthrough Device Designation for a novel implant system.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic initiatives. The company's growth and profitability improvements, along with new product launches, contribute to a favorable sentiment.

Positives

• SI-BONE achieved significant revenue growth and improved profitability in 2024.
• The company has a strong cash position, providing financial flexibility.
• New product launches and regulatory approvals are expected to drive future growth.
• Increased physician adoption of iFuse procedures indicates growing market acceptance.
• The company is focused on innovation, as evidenced by the Breakthrough Device Designation.

Future Outlook

The company anticipates continued growth driven by new product launches, increased physician adoption, and favorable reimbursement dynamics.

Management Comments

• Laura Francis, Chief Executive Officer, expressed gratitude for the SI-BONE team's performance and thanked stockholders for their continued confidence and support.
• Management is focused on introducing new products and continuing to train and educate physicians to grow the core business.

Industry Context

SI-BONE operates in the musculoskeletal disorder market, specifically targeting sacropelvic anatomy. The company's focus on minimally invasive surgical implant systems positions it to capitalize on the growing demand for less invasive procedures.

Comparison to Industry Standards

• The document mentions a compensation peer group including Alphatec Holdings, Nevro, RxSight, AxoGen, Orthofix Medical, Sight Sciences, Cerus, OrthoPediatrics, Silk Road Medical, Cutera, Paragon 28, STAAR Surgical Company, Glaukos, PROCEPT BioRobotics, Treace Medical Concepts, LeMaitre Vascular, Pulmonx, and Zynex.
• These companies are used to benchmark executive compensation levels.
• The document also mentions the S&P Healthcare Equipment Select Index as a reference for relative TSR performance.

Stakeholder Impact

• Shareholders will benefit from the company's improved financial performance and strategic initiatives.
• Employees are recognized for their contributions to the company's success.
• Patients will have access to innovative medical devices for sacropelvic disorders.
• Healthcare professionals will receive training and education on SI-BONE's products.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will continue to focus on new product development and physician training.
• Management will continue to engage with stockholders on executive compensation and governance topics.

Key Dates

Keywords

SI-BONE, iFuse, Annual Meeting, Revenue, Adjusted EBITDA, Medical Device, Sacroiliac Joint Dysfunction, Implants, Breakthrough Device Designation, Proxy Statement